E for L Aim Public Co., Ltd. NVDR

E for L Aim Public Co., Ltd. NVDR

0.10
THB
-0.01
(-9.09%)
0.01EPS
12.29P/E
519.80MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.26
1.58
4.9
3.43
1.62
0.91
0.6
0.52
0.59
0.37
0.33
0.34
0.33
0.29
Basic EPS, GAAP
0.04
0.28
0.23
-0.57
-0.76
-0.07
-0.08
-0.09
0.22
0.01
- -
- -
0.01
0.01
Free Cash Flow per Basic Share
- -
-0.16
-0.06
-0.53
0.17
-0.07
-0.01
0.09
-0.02
0.05
- -
0.03
0.03
- -
Dividend per Share
- -
- -
0.1
0.17
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.76
1.04
1.42
0.7
0.08
0.14
0.1
0.23
0.1
0.13
0.13
0.14
0.15
0.15
Tangible Book Value per Share
0.75
-3.66
-3.29
-1.84
-0.94
-0.24
-0.13
0.22
0.09
0.12
0.13
0.13
0.14
0.15
Basic Weighted Avg Shares
604
920
920
1,071
1,526
2,274
3,222
3,222
3,687
3,998
3,998
3,998
3,998
3,998
Sales/Revenue/Turnover
158
1,450
4,504
3,673
2,474
2,060
1,921
1,667
2,165
1,492
1,310
1,340
1,306
1,168
Operating Margin (%)
9.88
18.33
12.54
-8.18
-15.35
-2.67
-8.99
2.29
12.36
4.5
2.82
3.09
4.68
5.05
Depreciation Expense
18
31
214
225
226
112
95
92
60
46
46
53
52
52
Net Income, GAAP
26
259
210
-614
-1,163
-166
-273
-299
812
53
13
20
45
42
Effective Tax Rate (%)
5.85
13.2
28.34
- -
- -
- -
- -
- -
0.03
4.82
1.5
13.49
- -
- -
Profit Margin (%)
16.72
17.83
4.67
-16.73
-47.02
-8.07
-14.19
-17.94
37.5
3.55
1.03
1.47
3.41
3.62
Working Capital
674
-828
-1,194
-1,668
-1,432
-690
-1,051
-1,052
428
345
250
262
295
294
LT Debt
- -
2,370
862
404
680
428
5
81
500
326
218
196
138
108
Total Equity
698
1,949
2,998
1,988
-96
277
-105
-742
393
506
525
544
583
593
Return on Invested Capital (%)
7.22
8.1
4.6
- -
- -
- -
- -
- -
111.22
7.19
4.25
5.05
- -
- -
Return on Capital (%)
7.23
9.25
6.36
- -
- -
- -
- -
- -
121.76
7.19
4.25
5.05
- -
- -
Return on Common Equity (%)
7.26
31.27
18.61
-54.19
-212.6
-57.96
-71.14
-56.52
144.11
11.8
2.6
3.68
7.91
7.36

Capital Structure

THB

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
162
160
164
LT Borrowings
130
115
100
LT Finance Leases
9
8
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3,998
3,998
3,998
Market Capitalization
600
520
520

Working Capital

THB

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
792
713
695
Cash, Cash Equivalents & STI
22
28
19
Accounts Receivable, Net
327
264
247
Inventories
400
378
362
Total Current Liabilities
497
426
401
Payables & Accruals
326
256
223
ST Debt
162
160
164
Deferred Revenue
7
9
13

Growth Rates

THB

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-16.62%
-21.92%
7.16%
Free Cash Flow
-1,757.3%
-3,285.11%
-16.28%
Net Income, GAAP
-68.15%
-73.34%
126.34%
Sales/Revenue/Turnover
-10.15%
-2.74%
-2.57%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
248
249
399
443
1,340
2025
297
352
324
333
1,306
2026
259
252
- -
- -
- -

Quarterly Earnings Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.01
0.01
0.01
- -
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Preecha Nuntnarumit
Full Time Employees
3,058
Sector
Distribution services
Industry
Medical distributors
Address
432 Rajhaviti Road Bangkok BM Thailand 10700
IPO Date
Feb 19, 2009
Business
E for L Aim Public Company Limited is a Thailand-based distributor of medical devices and equipment, primarily serving the healthcare sector through its subsidiaries. The company offers clinical hematology analyzers, microscopy systems, chemistry and immunology diagnostic equipment, microbiology testing products; educational, clinical, and laboratory microscopes; scientific research microscopes; blood bank reagents and equipment; and health and beauty products including cosmetics, healthy drinks, dietary supplements, and snail slime formulations. Incorporated in 2005 and headquartered in Bangkok, Thailand, it concentrates operations within the domestic market, targeting hospitals, laboratories, and research institutions with a focus on diagnostic and laboratory solutions. Recent financial statements for 2024 and the first quarter of 2025 reflect ongoing audited operations with unqualified opinions from BDO Audit Company Limited, alongside stable market positioning evidenced by consistent stock exchange listings and key metrics such as a price-to-earnings ratio of approximately 9.12x and current ratio of 1.41 as of late 2025.